Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes
Deuvacracitinib (Sotyktu), which the FDA approved in September 2022, is a first-of-its-class tyrosine kinase 2 inhibitor and a member of the Janus kinase family.
Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.
Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of Treatment With Prolia Was Associated... | May 8, 2023
An analysis of data from the National Inpatient Sample offers an overview of risk for adverse delivery outcomes associated with Takayasu arteritis among a real-world cohort of US-based patients.